Page 4,853«..1020..4,8524,8534,8544,855..4,8604,870..»

Gene and Stem Cell Therapy Combination Could Aid Wound Healing

Posted: Published on October 10th, 2013

Johns Hopkins Medicine Media Relations and Public Affairs JOHNS HOPKINS MEDICINE NEWS TIPS FROM THE 2013 ANNUAL CLINICAL CONFERENCE OF THE AMERICAN COLLEGE OF SURGEONS, OCT. 6-10, WASHINGTON, D.C. GENE AND STEM CELL THERAPY COMBINATION COULD AID WOUND HEALING --Findings in elderly mice offer insight into helping elderly people recover from burns Newswise Johns Hopkins researchers, working with elderly mice, have determined that combining gene therapy with an extra boost of the same stem cells the body already uses to repair itself leads to faster healing of burns and greater blood flow to the site of the wound. Their findings offer insight into why older people with burns fail to heal as well as younger patients, and how to potentially harness the power of the bodys own bone marrow stem cells to reverse this age-related discrepancy. As we get older, it is harder for our wounds to heal, says John W. Harmon, M.D., a professor of surgery at the Johns Hopkins University School of Medicine, who will present his findings to the American College of Surgeons Surgical Biology Club on Sunday at 9 a.m. Our research suggests there may be a way to remedy that. To heal burns or other … Continue reading

Comments Off on Gene and Stem Cell Therapy Combination Could Aid Wound Healing

GNT Biotech and Medicals Corporation Licenses Novel Cancer Molecule from Shenzhen Chipscreen Biosciences Ltd.

Posted: Published on October 10th, 2013

SHENZHEN, China, Oct. 10, 2013 /PRNewswire/ -- GNT Biotech and Medicals Corporation announces the grant of an exclusive license from Shenzhen Chipscreen Biosciences Ltd.for the development and commercialization of Chidamide in Taiwan. Chidamide, an oral, selective histone deacetylase (HDAC) inhibitor, is currently being evaluated in Phase II trials by Chipscreen Biosciences in Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL) and Non-Small Cell Lung Cancer patients (NSCLC). GNTbm will develop and commercialize Chidamide primarily in PTCL, NSCLC and will also retain the rights to develop and commercialize Chidamide in other oncology indications in Taiwan. About Chidamide Chidamide is a selective HDAC inhibitor against subtype 1, 2, 3 and 10, and being studied in multiple clinical trials as a single agent or in combination with chemotherapeutic agents for the treatment of various hematological and solid cancers. Its anticancer effects are thought to be mediated through epigenetic modulation via multiple mechanisms of action, including the inhibition of cell proliferation and induction of apoptosis in blood derived cells, inhibition of epithelial to mesenchymal transition (EMT, a process that is highly relevant to tumor cell metastasis and drug resistance), induction of tumor specific antigen and antigen-specific T cell cytotoxicity, enhancement of NK cell anti-tumor … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on GNT Biotech and Medicals Corporation Licenses Novel Cancer Molecule from Shenzhen Chipscreen Biosciences Ltd.

Amniotic stem cells show promise in helping to repair cardiac birth defects

Posted: Published on October 10th, 2013

Public release date: 9-Oct-2013 [ | E-mail | Share ] Contact: Sally Garneski pressinquiry@facs.org 312-202-5409 American College of Surgeons WASHINGTON, DCResearchers at the University of Michigan Department of Surgery have begun testing an alternative to embryonic stem cells that could one day regenerate muscle tissue for babies with congenital heart defects. A research-in-progress report on this new approach, which uses amniotic stem cells, was presented today at the 2013 Clinical Congress of the American College of Surgeons. Although this research is still in an early phase, this new approach has the potential to one day help thousands of babies born each year with congenital heart defects. Typically, a pregnant woman can have a fetal ultrasound performed to find out the sex of her baby between 18 and 20 weeks gestation. But each year during pregnancy or after birth, 40,000 women also find out that their babies have birth defects in their hearts, according to the Centers for Disease Control and Prevention.* Babies with congenital heart defects often go through multiple heart operations or even a transplant before their first birthday. But Shaun Kunisaki, MD, a pediatric surgeon and assistant professor of surgery at the University of Michigan, and his surgical … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Amniotic stem cells show promise in helping to repair cardiac birth defects

The Low Vision Exam: Low Vision Specialists of Maryland and Virginia #3: – Video

Posted: Published on October 10th, 2013

The Low Vision Exam: Low Vision Specialists of Maryland and Virginia #3: Low Vision Specialists of MD and VA help those with Macular Degeneration, Diabetic Retinopathy, Stargardt's Disease, and Retinitis Pigmentosa by providing a ... By: Thomas Azman … Continue reading

Posted in Retinitis Pigmentosa | Comments Off on The Low Vision Exam: Low Vision Specialists of Maryland and Virginia #3: – Video

Scientists Found Novel Way To "Switch on" Tumour Suppressors That Have Been Silenced

Posted: Published on October 10th, 2013

Newswise A team of scientists from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) and their collaborators from the Harvard Stem Cell Institute have found that a novel noncoding ribonucleic acid (RNA) offers the potential for "switching on" of tumour suppressors that have been shut off. The research group, led by Professor Daniel Tenen, Director of CSI Singapore, demonstrated for first time that RNA interacts with an enzyme essential for DNA methylation, known as DNA methyl transferase 1 (DNMT1), offering strategies for the treatment of diseases such as cancer. In this study, the researchers focused on a new class of RNAs, which is critical in regulating DNA methylation. This is a process in which certain building blocks of DNA, the genetic code, are chemically modified without resulting in a change in the code itself. DNA methylation is associated with silencing of gene expression and found in many diseases. For example, in cancer, genes called tumour suppressors, which inhibit tumour formation, are often silenced or shut off in the cancer cells, and this is associated with DNA methylation. This novel study was first published online in the research journal Nature on 9 October 2013. … Continue reading

Comments Off on Scientists Found Novel Way To "Switch on" Tumour Suppressors That Have Been Silenced

StemCells, Inc. to Present at 2013 Stem Cell Meeting on the Mesa's Regen Med Partnering Forum

Posted: Published on October 10th, 2013

NEWARK, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM), the leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, announced today that President and CEO Martin McGlynn will make a presentation on the Company's programs and operations at the Regen Med Partnering Forum during the 2013 Stem Cell Meeting on the Mesa, to be held October 14-16. Mr. McGlynn is scheduled to speak at 11:00 a.m. Pacific Time on Monday, October 14, at the Estancia La Jolla Hotel in La Jolla, Calif. A live video webcast of all company presentations will be available at: http://stemcellmeetingonthemesa.com/webcast/ and will also be published on the Alliance for Regenerative Medicine's (ARM) website shortly after the event. The Stem Cell Meeting on the Mesa is a three-day conference organized by the Sanford Consortium for Regenerative Medicine, the California Institute for Regenerative Medicine (CIRM), and ARM. The conference brings together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. The first two days of the conference, October 14-15, features the Regen Med Partnering Forum, the only partnering meeting organized specifically for the regenerative medicine and advanced therapies industry. … Continue reading

Comments Off on StemCells, Inc. to Present at 2013 Stem Cell Meeting on the Mesa's Regen Med Partnering Forum

Fire Fighters Team Up to Fill the Boot for MDA

Posted: Published on October 9th, 2013

Salt Lake City (PRWEB) October 07, 2013 Fire fighters will be out on the streets this week throughout the Salt Lake Valley asking motorists to help Fill the Boot for the Muscular Dystrophy Association. Beginning today through Saturday, Oct. 12.,every dollar that passing motorists can pitch into the fire fighters boots helps Unified Fire Authority Local1696 fire fighters provide medical treatment and support services to individuals and their families living with neuromuscular diseases in the state of Utah. The International Association of Fire Fighters has been a national MDA partner for more than 50 years and remains committed to the fight to end neuromuscular diseases. Fire fighters are American heroes who make such a difference for the people and families we serve, said MDA Executive Director Jamie Ingersoll. The funds they raise are used for health care services and equipment support, and to help send kids to free MDA summer camps. We are grateful for everything they do. Fill the Boot funds also are used to support some of the 250 worldwide research projects seeking better treatments and cures for the more than 40 neuromuscular diseases covered by MDA, including Duchenne muscular dystrophy, spinal muscular atrophy and ALS. IAFF became … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Fire Fighters Team Up to Fill the Boot for MDA

Somerhalder petitions for medical marijuana

Posted: Published on October 9th, 2013

Ian Somerhalder is petitioning for the legalisation of a form of medical marijuana used to treat children who suffer from epilepsy. The Vampire Diaries star took to Twitter this week to share the story of a nine-month-old girl named Kaitlyn Pogson. According to the Toronto Star, Kate suffers from a severe form of epilepsy that causes her to suffer up to 300 seizures a day and her parents are fighting for her to receive alternative treatment. A petition was started on website Change.org to fight for the young girl to be prescribed a special strain of marijuana supporters believe could reduce the number of seizures she experiences due to Dravet syndrome. RT @DevonHaas: WE NEED 18 MORE PEOPLE TO SIGN THIS! SIGN AND RT! #doitforKim, Ian wrote, including a link to the petition. According to the draft, penned by Pediatric CBD Canada, Kaitlyns special access to the drug Cannabidiol (CBD) was denied. The petition goes on to state that CBD is a non-psychoactive extract of marijuana that does not create a high and has no observed side effects. CBD has produced incredibly positive results in the United States for not just Dravet Syndrome but all medically refractory epilepsies. Many children … Continue reading

Comments Off on Somerhalder petitions for medical marijuana

CureMark’s drug uses digestive system to treat autism, raises $18.5M in runup to NDA submission

Posted: Published on October 9th, 2013

The causes of autism and how prevalent it really is have been the stuff of impassioned debate and controversy. It has stirred a variety of opinions from its definition to diagnosis tools to the best treatment approach. A biotechnology company has developed a treatment for the disorder by focusing on the physiology. CureMark takes the view that digestive enzyme problems are a major component of autism. It argues that bodys inability to digest certain proteins affects amino acid production, which can interfere with brain function. New York-based CureMark has raised $18.5 million as it prepares to submit a new drug application for its enzyme replacement therapy to the U.S. Food and Drug Administration, the company said in the statement. Earlier this year it completed a Phase 3 multicenter clinical trial of CM-AT for autism. The drug met primary and secondary endpoints in the double-blind, randomized, placebo-controlled study of children with autism aged 3 to 8. A European institutional investor led the financing round according to the statement. Other investors identified on AngelList are Kimball Duncan and Allan Johnston. CM-AT was designated as a Fast Track drug in 2010 by the FDA. Drugs that qualify for that classification are for the … Continue reading

Comments Off on CureMark’s drug uses digestive system to treat autism, raises $18.5M in runup to NDA submission

Center for Autism and Related Disorders Awarded $750,000 Grant from the State of Texas to Provide Therapy to …

Posted: Published on October 9th, 2013

Austin, Texas (PRWEB) October 08, 2013 Center for Autism and Related Disorders (CARD), Inc., today announces the receipt of a $750,000 Autism Program grant from the Texas Department of Assistive and Rehabilitative Services (DARS). The grant will allow CARD to provide home-based, center-based, and school services for up to two years to underserved children with autism spectrum disorder (ASD) who live in Austin and outlining areas. "We are excited that Texas has allocated the resources to ensure that children affected by autism get the treatment they need to lead happy, healthy lives," says Operations Manager Dorothy Light, M.A. "Our team will partner with the families, teachers, and administrators to ensure these children see measurable results from their behavioral treatment." According to the Centers for Disease Control and Prevention (CDC), one in every 88 children in America is diagnosed with ASD, making autism more prevalent than pediatric cancer, juvenile diabetes, and childhood AIDS combined. The Ad Hoc Request Texas Health and Human Services Commission GIS/Demographic Team estimates 26,700 children in Texas, between the ages of three and eight years old, are diagnosed with autism. The Autism Program will help the state identify models that best serve these children and will enable … Continue reading

Comments Off on Center for Autism and Related Disorders Awarded $750,000 Grant from the State of Texas to Provide Therapy to …

Page 4,853«..1020..4,8524,8534,8544,855..4,8604,870..»